Linfoma de células B de alta calidad con MYC y BCL2 y/o rearreglos BCL6 (doble golpe / triple golpe)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DIS-HGBL-DH |
|---|---|
| Tipo | Enfermedad |
| Aliaces | DH/THLLinfoma con doble impactoHGBLHGBL-DHLinfoma de células B de alto grado, double-hit / triple-hitВисокозлоякісна B-клітинна лімфома з MYC + BCL2/BCL6 (double-hit / triple-hit) |
| Situación | reviewed 2026-04-25 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9680/3 |
|---|---|
| icd_10 | C83.3 |
| who_classification | Aggressive B-cell lymphomas — High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements per WHO 5th ed. |
Notas
Mandatory FISH break-apart for MYC + BCL2 + BCL6 on every newly- diagnosed DLBCL — without it, double-hit is missed. Distinct from Burkitt (Ki67 ~100%, BCL2−) by Ki67 typically 70-90% + BCL2+.
Utilizado por
Relevancia terapéutica
BMA-BCL2-REARRANGEMENT-HGBL-DH- BCL2-R como socio de MYC-R define HGBL-DH. La misma gestión que la célula MYC-R: DA-EPOCH-R...BMA-MYC-REARRANGEMENT-HGBL-DH- HGBL con MYC + BCL2 (y/o BCL6) reordenamientos ('doble golpe' / 'triple golpe') tiene agre...
Algoritmos
ALGO-HGBL-DH-1L- ALGO-HGBL-DH-1LALGO-HGBL-DH-2L- ALGO-HGBL-DH-2L
Enfermedad
DIS-BURKITT- Linfoma de BurkittDIS-DLBCL-NOS- Linfoma B-Cell grande difuso, NOS
Indicación
IND-HGBL-DH-1L-DAEPOCHR- IND-HGBL-DH-1L-DAEPOCHRIND-HGBL-DH-1L-RCHOP- IND-HGBL-DH-1L-RCHOPIND-HGBL-DH-2L-CART-AXICEL- IND-HGBL-DH-2L-CART-AXICEL
Cuestionarios
QUEST-HGBL-DH-1L-STUB- Linfoma de alta calidad de células B, doble golpe / triple golpe — primera línea
Señal de alerta
RF-DLBCL-HIGH-RISK-BIOLOGY- Biología de alto riesgo en DLBCL NOS: doble expresión (MYC + BCL2 por IHC, sin reorganización), T...RF-HGBL-DH-CNS-PROPHYLAXIS-TRIGGER- HGBL double-/triple-hit lymphoma — biology alone meets CNS-prophylaxis indication indepen...RF-HGBL-DH-EMERGENCY-TLS- High-grade B-cell lymphoma double-/triple-hit with active or imminent TLS at diagnosis: L...RF-HGBL-DH-FRAILTY-AGE- Edad > 75 O ECOG ≥3 - toxicidad DA-EPOCH-R prohibitiva; R-CHOP modificado + IT MTX profilaxi...RF-HGBL-DH-HIGH-RISK-BIOLOGY- MYC + BCL2 (and/or BCL6) rearrangement (double-/triple-hit) confirmed by FISH — DA-EPOCH-...RF-HGBL-DH-INFECTION-SCREENING- Serología obligatoria del VHB/VHC/VIH pre-rituximab; HGBL-DH asociada al VIH obtiene cART...RF-HGBL-DH-ORGAN-DYSFUNCTION- Disfunción cardíaca (LVEF <50%) - DA-EPOCH-R (preferido para HGBL-DH/-TH) es antraciclina...RF-HGBL-DH-TRANSFORMATION-PROGRESSION- PET-2 progression (Deauville 4-5 with new lesions) or end-of-induction non-CR — HGBL-DH r...
Fuentes
SRC-ESMO-DLBCL-2024- Orientación de práctica clínica de ESMO sobre linfoma difuso grande de células BSRC-ESMO-LYMPHOMA-2025- Linfomas: Guía de Práctica Clínica ESMO para el diagnóstico, tratamiento y seguimiento